Respreeza® Self-administration and Learning Program (AmAREtTI Study)

Inclusion Criteria

• •Adult patients (age ≥18 years old).
• •Patients suffering from AATD treated by Respreeza® through a peripheral vein at home for at least 3 month (consecutives or not). The 3-month period of treatment with Respreeza® does not necessarily correspond to the 3 months prior to inclusion.
• •Patient accompanied by a third person at home
• •Patients deemed to be suitable by the investigator for self-administration.
• •Patients with a life expectancy of over 3 years.
• •Patients who have been informed verbally and in writing via the information leaflet and who have signed the informed consent form.